论文部分内容阅读
目的 探讨血清新喋呤、可溶性CD8(sCD8)在原发性胆囊癌患者中的变化及意义。方法 采用酶联免疫吸附法测定血清新喋呤和sCD8水平。 结果 胆囊癌患者血清新喋呤水平[(5.86±5.85)ng/ml]高于正常对照组[(1.37±0.75)ng/ml] ,中晚期组[(6.85±6.25)ng/ml]高于早期组[(2.27±1.16)ng/ml] ,中晚期和早期组均高于正常对照组 (均P<0.05)。胆囊癌患者血清sCD8水平[(18.68±11.7)U/L]高于正常对照组[(9.89±3.13)U/L] ,中晚期组[(21.38±11.8)U/L]高于早期组[(8.93±3.13)U/L] ,差别均有非常显著性意义 (均P<0.01)。胆囊癌患者血清新喋呤与sCD8水平呈正相关 (r=0.63,P<0.01)。结论 胆囊癌患者血清新喋呤及sCD8水平升高 ,并与肿瘤进展有关。
Objective To investigate the changes and significance of serum neopterin and soluble CD8 (sCD8) in patients with primary gallbladder carcinoma. Methods Serum neopterin and sCD8 levels were determined by enzyme-linked immunosorbent assay. Results Serum neopterin level in patients with gallbladder carcinoma [(5.86±5.85) ng/ml] was higher than that in normal control group [(1.37±0.75) ng/ml], and it was higher in mid-advanced group [(6.85±6.25) ng/ml]. The early group [(2.27±1.16) ng/ml] was higher in the middle and late groups than in the normal group (all P<0.05). The serum sCD8 level in patients with gallbladder carcinoma [(18.68±11.7) U/L] was higher than that in the normal control group [(9.89±3.13) U/L], and that in the middle and late stage group [(21.38±11.8) U/L] was higher than that in the early group [ (8.93±3.13)U/L], the differences were all significant (all P<0.01). Serum neopterin was positively correlated with sCD8 level in patients with gallbladder carcinoma (r=0.63, P<0.01). Conclusion Serum levels of neopterin and sCD8 are elevated in patients with gallbladder carcinoma and are associated with tumor progression.